HomeQuestion

Do you extrapolate from the ALASCCA trial and offer adjuvant aspirin to patients with PIK3CA mutations in appendiceal cancer?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Are you planning to start running IHC HER2 testing on all tumor types, even those where HER2 overexpression is less typical, in light of tumor agnostic approval of trastuzumab deruxtecan?

Which PD-1 inhibitor will you use with chemotherapy in initial treatment of patients with metastatic anal cancer?

Is there role of HER2 directed therapy in adjuvant treatment of colon adenocarcinoma for tumors that are HER2 3+ by IHC?

Should atezolimab and chemotherapy be considered for stage III dMMR colon cancer with BRAF mutation?

What is your preferred chemotherapy backbone (FOLFOX or FOLFIRI) when combining with encorafenib + cetuximab in the 1L setting for BRAF V600E-mutant mCRC?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.